MALIGNANT MESOTHELIOMA
Clinical trials for MALIGNANT MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT MESOTHELIOMA trials appear
Sign up with your email to follow new studies for MALIGNANT MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug tazemetostat offered to patients with rare, aggressive tumors
Disease control NO_LONGER_AVAILABLEThis expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…
Matched conditions: MALIGNANT MESOTHELIOMA
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New Dual-Action antibody takes on advanced cancers
Disease control OngoingThis early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have spread or come back. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effect…
Matched conditions: MALIGNANT MESOTHELIOMA
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC